Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 224.1M shares rose 32.3% year over year, ahead of the +19.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +31.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +32.3% holds above the trailing-twelve-month pace of +19.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
224.1M+0.5% QoQ
Last fiscal yearDec 2025
187.24M+18.3% YoY
LTMMar 2026
200.88M+19.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.3%——
1 year+18.3%——
3-year CAGR+31.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
187.24M USD
Year-over-year change
+18.3%
4-year CAGR
+22.9%

Weighted Avg Shares (Diluted) vs competitors

How OCUL compares with its peers on the latest reported figures

  • OCUL's LTM Mar 2026 weighted avg shares (diluted) of 200.88M shares is the 3rd highest of the 11 companies compared; the peer median is 56.4M shares.
  • Its year-over-year change of +19.9% is the 3rd highest of 10, against a peer median of +9.9%.
  • Over three fiscal years its annual growth of +31.3% compares with a peer median of +10.2%.
OCUL Competitors Peer median
Weighted Avg Shares (Diluted) for OCUL and competitors
Company Period LTM YoY 3-year CAGR
BLCOBausch + Lomb CorporationLTM Jun 2026355.23M +0.6%+0.4%
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
OCULOcular Therapeutix, Inc.LTM Mar 2026200.88M +19.9%+31.3%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202677.28M +27.7%+25.2%
KODKodiak Sciences Inc.LTM Sep 202660.16M +14.0%+0.6%
GKOSGlaukos CorporationLTM Jun 202657.84M +3.1%+6.4%
OCSOculis Holding AGLTM Mar 202654.96M +27.5%+16.9%
STAASTAAR Surgical CompanyLTM Apr 202649.88M +0.7%+0.1%
HROWHarrow Health, Inc.LTM Mar 202637.93M +6.1%+10.2%
SGPSpyGlass Pharma, Inc. Common StockFY202533.43M ——
OTLKOutlook Therapeutics, Inc.LTM Mar 202628.35M +14.4%+33.9%
Peer median (excluding OCUL) 56.4M+9.9%+10.2%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.